Thais Baccili Cury Megid

Statistics

Publications

Citations

H-Index

Active since

2020

Affiliations

Thais Baccili Cury Megid is an author at Hospital Sírio-Libanês specializing in germline cancer susceptibility, programmed cell death protein 1 (pd-1) pathway, and pathogenic germline variants.

ORCID

Publications per year

2020–2022

Publications

Double heterozygous pathogenic variants prevalence in a cohort of patients with hereditary breast cancer

Thais Baccili Cury Megid, Mateus Camargo Barros‐Filho, Janina Pontes Pisani et al. · Frontiers in Oncology · 2022 · 21 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review

Aline Cristini Vieira, Thais Baccili Cury Megid, David Queiroz Borges Muniz et al. · Oxford Medical Case Reports · 2020 · 11 citations · Full text

Medicine, Immunology, Oncology +17

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study

Leandro Jonata de Carvalho Oliveira, Thais Baccili Cury Megid, Daniela Dornelles Rosa et al. · Therapeutic Advances in Medical Oncology · 2022 · 10 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

1–3 of 3